Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 5/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 4/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.40 |
| ▸ | QDPR | P09417 | 5/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 4/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5402902 | 0.81 | CA1 (0.45) | ESR2CYP2C19 | |
| SCHEMBL5394780 | 0.81 | ESR2 (0.39) | ESR2QDPRACMSD | |
| SCHEMBL5382437 | 0.80 | HSD17B1 (0.46) | ESR2HSD17B1HSD17B2QDPRACMSD | |
| SCHEMBL5439557 | 0.80 | ALDH1A1 (0.42) | ESR2QDPRTDP1CYP2C19ESR1 | |
| SCHEMBL503351 | 0.80 | ESR2 (0.44) | ESR2HSD17B1HSD17B2QDPRCYP3A4 | |
| SCHEMBL5387165 | 0.78 | ALOX5 (0.47) | ESR2HSD17B1QDPRACMSDESR1 | |
| SCHEMBL503196 | 0.77 | ESR2 (0.62) | ESR2QDPRTP53CYP3A4ESR1 | |
| SCHEMBL5389243 | 0.77 | GABRA1 (0.45) | ESR2HSD17B1QDPRACMSD | |
| SCHEMBL14560140 | 0.77 | ESR2 (0.54) | ESR2QDPRESR1 | |
| SCHEMBL5388046 | 0.76 | ALOX5 (0.39) | ESR2HSD17B1QDPRTP53TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196232-B2 | 4,4′-dihydroxyphenyl bicyclohexenes | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2007-03-27 | — | — | US | claimed |
| US-20060129001-A1 | Novel 4,4'-dihydroxyphenyl bicyclohexenes | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2006-06-15 | — | — | US | claimed |
| US-9310681-B2 | Negative resist composition and patterning process using same | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-04-12 | — | — | US | disclosed |
| US-9310681-B2 | Negative resist composition and patterning process using same | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-04-12 | — | — | US | disclosed |
| US-20150198883-A1 | NEGATIVE RESIST COMPOSITION AND PATTERNING PROCESS USING SAME | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2015-07-16 | — | — | US | disclosed |
| US-20150198883-A1 | NEGATIVE RESIST COMPOSITION AND PATTERNING PROCESS USING SAME | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2015-07-16 | — | — | US | disclosed |
| US-20120029215-A1 | METHOD FOR MANUFACTURING TRIMELLITIC ANHYDRIDE ARYL ESTER | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-2383265-A1 | METHOD FOR MANUFACTURING TRIMELLITIC ANHYDRIDE ARYL ESTER | Honshu Chemical Industry Co., Ltd. (JP) | 2011-11-02 | — | — | EP | disclosed |
| US-7196232-B2 | 4,4′-dihydroxyphenyl bicyclohexenes | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2007-03-27 | — | — | US | disclosed |
| US-7196232-B2 | 4,4′-dihydroxyphenyl bicyclohexenes | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2007-03-27 | — | — | US | disclosed |
| US-20060129001-A1 | Novel 4,4'-dihydroxyphenyl bicyclohexenes | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029215-A1 | METHOD FOR MANUFACTURING TRIMELLITIC ANHYDRIDE ARYL ESTER | TRIM4, CA6, TRIM58 | ESR2 4574/4885HSD17B1 552/4885HSD17B2 489/4885 |
| US-20060129001-A1 | Novel 4,4'-dihydroxyphenyl bicyclohexenes | DBF4, DCUN1D4, SDC4 | ESR2 2548/4885HSD17B1 2133/4885HSD17B2 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.